10:57 , May 7, 2019 |  BioCentury  |  Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
18:37 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million on March 13 in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated. Escalier plans to begin clinical trials...
22:16 , Mar 13, 2018 |  BC Extra  |  Financial News

Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated. Escalier plans to begin clinical trials in mid-2018 of...
04:10 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Dutch NASH play NorthSea debuts with €25M

On Dec. 12, former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round...
09:15 , Dec 12, 2017 |  BC Extra  |  Financial News

Dutch NASH play NorthSea debuts with €25M

Former Dezima Pharma B.V. investors and executives have reconnected to launch non-alcoholic steatohepatitis company NorthSea Therapeutics B.V. (Naarden, the Netherlands). The newco raised €25 million ($29.5 million) in a series A round led by Forbion...
20:23 , Nov 3, 2017 |  BC Week In Review  |  Financial News

BioGeneration closes Ventures Fund III at EUR82M

On Oct. 31, BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation...
21:37 , Nov 2, 2017 |  BioCentury  |  Finance

Bigger in Benelux

BioGeneration Ventures parlayed two major wins from its second fund into its largest fund to date, and now has the capital reserves for follow-on investments so the firm can retain more value in portfolio companies....
00:01 , Oct 31, 2017 |  BC Extra  |  Financial News

BioGeneration closes third fund

European VC BioGeneration Ventures announced the final close of BioGeneration Ventures Fund III at €82 million ($95.3 million). The fund's LPs included two strategic investors, Bristol-Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson Innovation --...
02:28 , Jul 13, 2017 |  BC Week In Review  |  Financial News

VarmX completes seed financing

On June 27, hemostasis and thrombosis company VarmX B.V. (Leiden, the Netherlands) said it raised an undisclosed sum in the final closing of a seed round from new investors BioGeneration Ventures and InnovationQuarter. VarmX B.V....